Trial Profile
Phase II trial of immunogenicity and reactogenicity of V 710 for the prevention of Staphylococcus aureus infections in patients with end-stage renal disease undergoing haemodyalysis
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2010
Price :
$35
*
At a glance
- Drugs V-710 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co
- 23 Nov 2010 New trial record
- 18 Nov 2010 Initial top-line results have been reported in an Intercell AG media release.